+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Peptide Therapeutics Market by Technology (Hybrid Phase, Liquid Phase, Solid Phase), Drug Class (Adrenocorticotropic Hormone, Calcitonin, Insulin), Route of Administration, Application, End User, Manufacturing Type - Forecast 2024-2030

  • PDF Icon

    Report

  • 187 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 4968565
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Peptide Therapeutics Market grew from USD 33.06 billion in 2023 to USD 35.76 billion in 2024. It is expected to continue growing at a CAGR of 8.35%, reaching USD 57.97 billion by 2030.

These biologically active molecules possess unique properties, making them an efficient drug development and pharmaceutical research option. The surging prevalence of chronic diseases, including cancer and diabetes, is raising the need for effective treatment options and an improved understanding of protein-protein interactions leading to targeted therapies. The growing investment in research & development activities and a robust clinical pipeline with therapeutic candidates result in novel peptide therapeutics being developed. However, the inherent instability of peptides and the high cost of manufacturing peptides may adversely impact the development of peptide therapeutics. Moreover, recent developments in drug delivery systems and the development of new peptides are expected to expand the potential applications for peptides.

Regional Insights

The peptide therapeutics market is evolving in the Americas due to well-established pharmaceutical industries, increased research activities, and a growing number of approved peptide drugs. Patent activity in this region is notable, with several major pharmaceutical companies headquartered in the area. In recent years, investments in innovative peptide formulations have increased, indicating a robust market potential for new therapeutic approaches. The rising prevalence of chronic disease, improving healthcare infrastructure, and growing awareness regarding peptide therapeutics are encouraging the growth of the peptide therapeutics market in the APAC region. In addition, ongoing advancements and the development of efficient, scalable, and cost-effective synthetic strategies for producing peptides are anticipated to encourage the adoption of peptide therapeutics globally. The peptide therapeutics market is developing in the EMEA region owing to the regulatory framework supporting innovation within biotechnology and funding research projects related to peptide therapeutics. The European Union demonstrates a well-established market for peptide therapeutics, supported by comprehensive healthcare systems and a high degree of awareness regarding advanced treatment options. The EU's regulatory framework, through the European Medicines Agency (EMA), has been instrumental in approving and monitoring peptide-based drugs. The peptide therapeutics market in the African region is currently growing steadily, characterized by growing research activities and increasing awareness toward advanced therapeutic options.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Peptide Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Prevalence of chronic diseases and need for effective therapeutic options
  • Exponential use of peptides in aesthetic dermatology

Market Restraints

  • Adverse recalls of peptide therapeutics

Market Opportunities

  • Ongoing R&D activities for new peptide development worldwide
  • Shift toward personalized medicine and identification of peptide biomarkers

Market Challenges

  • Production complexity and bioavailability issues of peptide therapeutics

Market Segmentation Analysis

  • Technology: Rising utilization of solid phase approach for synthesis of complex peptides
  • Drug Class: Increasing need for insulin to regulate glucose metabolism for type 1 and type 2 diabetes
  • Route of Administration: Rising adoption of intravenous administration due to peptide therapeutics immediacy and effectiveness in acute hospital care settings
  • Application: Widening use of peptide therapeutics in cardiovascular disorders to simulate the action of endogenous peptides involved in blood pressure regulation
  • End User: Expanding the use of peptide therapeutics in hospitals and clinics to address and manage patient conditions
  • Manufacturing Type: Increasing adoption of CMOs owing to the need for specialized manufacturing capabilities and the ability to scale production rapidly

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Peptide Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Peptide Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Expansion of GMP Capacities at CordenPharma Frankfurt: Elevating Early-Phase Peptide API Manufacturing

CordenPharma introduced new GMP capacities at its Frankfurt site, marking a significant step in its ongoing efforts to support early clinical phase drug development. Slated for full operational readiness in Q2 2024 with authorization from German authorities expected in H2 2024, this expansion adds 1000 m² of manufacturing space featuring cutting-edge Solid Phase Peptide Synthesis (SPPS) and High-Pressure Liquid Chromatography (HPLC), among other technologies. This initiative highlights CordenPharma’s commitment to integrated service offerings, linking Peptide Drug Substance production in Frankfurt with Injectable Drug Products in Caponago (Italy), thus facilitating efficient Investigational New Drug (IND) / Investigational Medicinal Product Dossier (IMPD) submissions and the initiation of First In-Human (FIH) clinical trials.

Revolutionizing Peptide Therapeutics: Orbis Medicines Innovates for Oral Drug Delivery

Orbis Medicines emerged from stealth mode, indicating an advanced step in the field of peptide therapeutics with a substantial EUR 26 million seed funding led by Novo Holdings and Forbion. The company is at the forefront of developing peptide-based drugs that can be administered orally, offering a promising alternative to the conventional, and often burdensome, injectable biologics used for chronic conditions. The platform employs highly automated chemical synthesis and screening processes, accelerated by machine learning techniques, to rapidly produce potential drug candidates optimized for oral administration.

Expanding Facilities in Peptide Therapeutic Production: WuXi AppTec's Strategic Growth

WuXi AppTec advanced its manufacturing capabilities with the opening of two new peptide manufacturing facilities, located at Changzhou and the newly established Taixing site in Jiangsu, China. This expansion significantly enhanced the company’s Solid-Phase Peptide Synthesis (SPPS) capabilities, increasing its total reactor volume to 32,000 liters. Leveraging state-of-the-art digital operation systems, these facilities are equipped with automated solvent delivery mechanisms designed to optimize production consistency, reduce cycle times, and minimize human error.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Peptide Therapeutics Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Peptide Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AmbioPharm, Inc., Amgen Inc., Amide Technologies, Inc., AstraZeneca PLC, Bachem Holding AG, Biosynth Ltd., Bristol Myers Squibb Company, Cidara Therapeutics, Inc., Corden Pharma International GmbH, Cybrexa, Inc., Eccogene, Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Ipsen Group, IRBM S.p.A., Ironwood Pharmaceuticals, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Peptidream Co., Ltd., Perpetual Medicines Corporation, Pfizer Inc., Piramal Pharma Limited, PolyPeptide Group AG, RELIEF THERAPEUTICS Holding SA, Sanofi S.A., Sanyou Biopharmaceuticals Co., Ltd., Shanghai Full-Life Technologies Co, Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, WuXi AppTec Co., Ltd., and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Peptide Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Technology

  • Hybrid Phase
  • Liquid Phase
  • Solid Phase

Drug Class

  • Adrenocorticotropic Hormone
  • Calcitonin
  • Insulin
  • Leuprorelin
  • Octreotide
  • Vasopressin

Route of Administration

  • Intravenous Administration
  • Nasal & Pulmonary Administration
  • Oral Administration
  • Transdermal Administration

Application

  • Cardiovascular Disorders
  • Gastrointestinal Disorders
  • Infectious Disorders
  • Neurological Disorders
  • Oncology

End User

  • Hospitals & Clinics
  • Long-term Care Facilities
  • Research Laboratories

Manufacturing Type

  • Contract Manufacturing Organization
  • In-house

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • Indiana
  • Maryland
  • Massachusetts
  • Minnesota
  • New Jersey
  • New York
  • North Carolina
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Purchase of this report includes 1 year online access with quarterly updates

Purchase of this report includes 1 year online access with quarterly updates

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of chronic diseases and need for effective therapeutic options
5.1.1.2. Exponential use of peptides in aesthetic dermatology
5.1.2. Restraints
5.1.2.1. Adverse recalls of peptide therapeutics
5.1.3. Opportunities
5.1.3.1. Ongoing R&D activities for new peptide development worldwide
5.1.3.2. Shift toward personalized medicine and identification of peptide biomarkers
5.1.4. Challenges
5.1.4.1. Production complexity and bioavailability issues of peptide therapeutics
5.2. Market Segmentation Analysis
5.2.1. Technology: Rising utilization of solid phase approach for synthesis of complex peptides
5.2.2. Drug Class: Increasing need for insulin to regulate glucose metabolism for type 1 and type 2 diabetes
5.2.3. Route of Administration: Rising adoption of intravenous administration due to peptide therapeutics immediacy and effectiveness in acute hospital care settings
5.2.4. Application: Widening use of peptide therapeutics in cardiovascular disorders to simulate the action of endogenous peptides involved in blood pressure regulation
5.2.5. End User: Expanding the use of peptide therapeutics in hospitals and clinics to address and manage patient conditions
5.2.6. Manufacturing Type: Increasing adoption of CMOs owing to the need for specialized manufacturing capabilities and the ability to scale production rapidly
5.3. Market Trend Analysis
5.3.1. Expanding pharmaceutical R&D activities and growing government investment to strengthen the healthcare sector in the Americas
5.3.2. Significant public and private investment in advanced research facilities and technologies in the Asia-Pacific region
5.3.3. Enhancement in peptide manufacturing capabilities, exploring new application areas, and presence of major players in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis
6. Peptide Therapeutics Market, by Technology
6.1. Introduction
6.2. Hybrid Phase
6.3. Liquid Phase
6.4. Solid Phase
7. Peptide Therapeutics Market, by Drug Class
7.1. Introduction
7.2. Adrenocorticotropic Hormone
7.3. Calcitonin
7.4. Insulin
7.5. Leuprorelin
7.6. Octreotide
7.7. Vasopressin
8. Peptide Therapeutics Market, by Route of Administration
8.1. Introduction
8.2. Intravenous Administration
8.3. Nasal & Pulmonary Administration
8.4. Oral Administration
8.5. Transdermal Administration
9. Peptide Therapeutics Market, by Application
9.1. Introduction
9.2. Cardiovascular Disorders
9.3. Gastrointestinal Disorders
9.4. Infectious Disorders
9.5. Neurological Disorders
9.6. Oncology
10. Peptide Therapeutics Market, by End User
10.1. Introduction
10.2. Hospitals & Clinics
10.3. Long-term Care Facilities
10.4. Research Laboratories
11. Peptide Therapeutics Market, by Manufacturing Type
11.1. Introduction
11.2. Contract Manufacturing Organization
11.3. In-house
12. Americas Peptide Therapeutics Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Peptide Therapeutics Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Peptide Therapeutics Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.3.1. Expansion of GMP Capacities at CordenPharma Frankfurt: Elevating Early-Phase Peptide API Manufacturing
15.3.2. Revolutionizing Peptide Therapeutics: Orbis Medicines Innovates for Oral Drug Delivery
15.3.3. Expanding Facilities in Peptide Therapeutic Production: WuXi AppTec's Strategic Growth
15.3.4. Glenmark Pharmaceuticals Announces Biosimilar Liraglutide Launch in India to Revolutionize Anti-Diabetic Treatment
15.3.5. Amide Technologies' Novel Manufacturing Platform and Strategic Capital Advancement
15.3.6. Strategic Acquisition Elevates Pharmathen's Position in the Peptide Therapeutics Market
15.3.7. Biosynth Solidifies Market Position with Strategic Acquisition of Pepceuticals
15.3.8. Strategic Collaboration between PeptiDream and Genentech to Advance Peptide-Radioisotope Therapeutics
15.3.9. Merck and IRBM Forge Forward in Peptide Therapeutics: A Partnership to Expand and Innovate in Biopharmaceuticals
15.3.10. Fujitsu Launches Pioneering Bio-Drug Design Accelerator Focused on Advancing Peptide Therapeutics in Cancer and CNS Regeneration
15.3.11. Comprehensive Support for Peptide Therapeutics Development from Conception to Manufacturing for Introducing SynCrest's CRDMO Service
16. Competitive Portfolio
16.1. Key Company Profiles
16.2. Key Product Portfolio
List of Figures
FIGURE 1. PEPTIDE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. PEPTIDE THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. PEPTIDE THERAPEUTICS MARKET DYNAMICS
FIGURE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2023 VS 2030 (%)
FIGURE 18. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 22. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 27. PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 28. PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. PEPTIDE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LEUPRORELIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LEUPRORELIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OCTREOTIDE, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NASAL & PULMONARY ADMINISTRATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NASAL & PULMONARY ADMINISTRATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISORDERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISORDERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 49. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
TABLE 50. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
TABLE 51. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 52. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 53. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 54. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 55. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 56. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 57. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 58. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 59. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 60. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 61. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 62. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 63. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2023 (USD MILLION)
TABLE 64. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY REGION, 2024-2030 (USD MILLION)
TABLE 65. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 66. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 67. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 68. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 69. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 70. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 71. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 72. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 73. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 74. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 75. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 76. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 77. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 78. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 79. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 80. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 81. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 82. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 83. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 84. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 85. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 86. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 87. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 88. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 89. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 90. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 91. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 92. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 93. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 94. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 95. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 96. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 97. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 98. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 99. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 100. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 101. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 102. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 103. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 104. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 105. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 106. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 107. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 108. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 109. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 110. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 111. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 112. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 113. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 114. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 115. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 116. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 117. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 118. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 119. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 120. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 121. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 122. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 123. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 124. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 125. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 126. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 127. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 128. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 129. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 130. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 131. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 132. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 133. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 134. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 135. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 136. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 137. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 138. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 139. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 140. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 142. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 144. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 145. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 146. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 147. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 148. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 149. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 150. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 152. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 154. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 155. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 156. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 157. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 158. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 159. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 160. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 161. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 162. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 163. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 164. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 165. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 166. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 167. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 168. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 169. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 170. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 171. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 172. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 173. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 174. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 175. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 176. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 177. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 178. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 179. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 180. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 181. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 182. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 183. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 184. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 185. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 186. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 187. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 188. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 189. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 190. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 191. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 192. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 193. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 194. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 195. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 196. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 197. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 198. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 199. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 200. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 201. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 202. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 203. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 204. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 205. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 206. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 207. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 208. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 209. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 210. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 211. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 212. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 213. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 214. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 215. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 216. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 217. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 218. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 219. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 220. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 221. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 222. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 223. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 224. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 225. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 226. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 227. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 228. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 229. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 230. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 231. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 232. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 233. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 234. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 235. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 236. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 237. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 238. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 239. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 240. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 241. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 242. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 243. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 244. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 245. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 246. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 247. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 248. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 249. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 250. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 251. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 252. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 253. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 254. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 255. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 256. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 257. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 258. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 259. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 260. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 261. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 262. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 263. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 264. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 265. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 266. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 267. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 268. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 269. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 270. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 271. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 272. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 273. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 274. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 275. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 276. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 277. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 278. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 279. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 280. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 281. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 282. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 283. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 284. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 285. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 286. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 287. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 288. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 289. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 290. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 291. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 292. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 293. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 294. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 295. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 296. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 297. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 298. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 300. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 301. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 302. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 303. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 304. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 305. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 306. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 307. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 308. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 309. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 310. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 311. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 312. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 313. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 314. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 315. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 316. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 317. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 318. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 319. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 320. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 321. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 322. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 323. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
TABLE 324. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
TABLE 325. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 326. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 327. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 328. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 329. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 330. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 331. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 332. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 333. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 334. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • AmbioPharm, Inc.
  • Amgen Inc.
  • Amide Technologies, Inc.
  • AstraZeneca PLC
  • Bachem Holding AG
  • Biosynth Ltd.
  • Bristol Myers Squibb Company
  • Cidara Therapeutics, Inc.
  • Corden Pharma International GmbH
  • Cybrexa, Inc.
  • Eccogene
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Ipsen Group
  • IRBM S.p.A.
  • Ironwood Pharmaceuticals, Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Peptidream Co., Ltd.
  • Perpetual Medicines Corporation
  • Pfizer Inc.
  • Piramal Pharma Limited
  • PolyPeptide Group AG
  • RELIEF THERAPEUTICS Holding SA
  • Sanofi S.A.
  • Sanyou Biopharmaceuticals Co., Ltd.
  • Shanghai Full-Life Technologies Co, Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
  • WuXi AppTec Co., Ltd.
  • Zealand Pharma A/S

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages187
PublishedJune 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 35.76 Billion
Forecasted Market Value ( USD ) by 2030 $ 57.97 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal

Related Topics

Related Reports

Global Peptide Therapeutics Market Size, Share & Trends Analysis Report by Application (Cancer, Metabolic Disorders), Type (Generic, Innovative), Type of Manufacturer, Route of Administration, Synthesis Technology, Region, and Segment Forecasts, 2024-2030 - Product Image

Global Peptide Therapeutics Market Size, Share & Trends Analysis Report by Application (Cancer, Metabolic Disorders), Type (Generic, Innovative), Type of Manufacturer, Route of Administration, Synthesis Technology, Region, and Segment Forecasts, 2024-2030

  • Report
  • 110 Pages
  • Global
From
Peptide Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Peptide Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Peptide Therapeutics Global Market Report 2024 - Product Image

Peptide Therapeutics Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Peptide Therapeutics Market Report by Type, Type of Manufacturer, Synthesis Technology, Routes of Administration, Application, and Region 2024-2032 - Product Image

Peptide Therapeutics Market Report by Type, Type of Manufacturer, Synthesis Technology, Routes of Administration, Application, and Region 2024-2032

  • Report
  • 138 Pages
  • Global
From
Peptide Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Peptide Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.